Chen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chen Liu has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Shen Yue
Department of Medical Genetics, Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China
7 shared publications - Tingting Yu
Department of Medical Genetics Nanjing Medical University Nanjing China
5 shared publications Jing Cai
Department of Medical Genetics, Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, Jiangsu 211166, China
4 shared publicationsBinbin Gao
Department of Medical Genetics Nanjing Medical University Nanjing China
3 shared publicationsLun Kuang
Department of Medical Genetics Nanjing Medical University Nanjing China
3 shared publications- Steven Yan Cheng
Department of Medical Genetics, Nanjing Medical University, Nanjing, China
3 shared publications
Latest Publications
- Open Access
- 8 March 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3) , e70635
CMA‐mediated USP9X degradation promotes SHH medulloblastoma progression by facilitating SUFU ubiquitination
Background: Medulloblastoma (MB) represents the most prevalent malignant paediatric brain tumour, characterised by the sonic Hedgehog molecular subtype (SHH‐MB), which is driven by aberrant activation of the SHH signalling cascade. Suppressor of fused (SUFU), a core member of SHH signal transduction, functions as a tumour suppressor by inhibiting the activity of transcription factors glioma‐associated oncogene homologue (GLI)‐triggered SHH signalling pathway. While ubiquitin‐mediated proteasomal degradation of SUFU has been shown to modulate SHH signalling, the regulatory factors involved in SUFU deubiquitination and their specific roles in MB pathogenesis remain largely undefined. Methods: Mass spectrometry and co‐immunoprecipitation were employed to identify the interaction between USP9X and SUFU. Clinical correlation analyses were conducted using MB tissue microarrays and publicly available datasets. Ubiquitination assays, functional cell‐based experiments, and orthotopic xenograft models were performed to evaluate the biological role of USP9X in SHH‐MB. Chaperone‐mediated autophagy (CMA) inhibitors were utilised to investigate their regulatory effects on USP9X expression and SHH‐MB progression. Results: Mass spectrometry identified the deubiquitinase ubiquitin‐specific protease 9X (USP9X) as a previously unrecognised SUFU‐binding partner. Notably, USP9X and SUFU exhibit a positive correlation in a MB tissue array, with both exhibiting low expression levels that are associated with adverse prognostic outcomes. Loss of USP9X in SHH‐MB enhances cell proliferation in vitro as well as orthotopic MB xenograft tumourgenicity in vivo. Mechanically, USP9X deubiquitinates and stabilises SUFU, thereby negatively regulating SHH signal transduction. Interestingly, SHH signalling promotes SUFU ubiquitination through CMA‐dependent degradation of USP9X protein levels, facilitating pathway activation. Combined inhibition of CMA and SHH pathway had a synergically therapeutic effect on SHH‐MB. Conclusions: These results establish CMA and USP9X as pivotal regulators of SHH medulloblastoma MB progression, emphasising their potential as novel therapeutic targets for medulloblastoma, and combinatorial inhibition of CMA and Smoothened (SMO) may provide a strategy to overcome intrinsic or acquired resistance to SMO monotherapy in SHH‐MB. Key points: USP9X suppresses SHH medulloblastoma progression by deubiquitinating SUFU. SHH promotes USP9X degradation through the CMA pathway. Combined inhibition of CMA and SHH pathway had a synergically therapeutic effect on SHH Medulloblastoma.
- 8 March 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3) , e70635
Open AccessCMA‐mediated USP9X degradation promotes SHH medulloblastoma progression by facilitating SUFU ubiquitination
Background: Medulloblastoma (MB) represents the most prevalent malignant paediatric brain tumour, characterised by the sonic Hedgehog molecular subtype (SHH‐MB), which is driven by aberrant activation of the SHH signalling cascade. Suppressor of fused (SUFU), a core member of SHH signal transduction, functions as a tumour suppressor by inhibiting the activity of transcription factors glioma‐associated oncogene homologue (GLI)‐triggered SHH signalling pathway. While ubiquitin‐mediated proteasomal degradation of SUFU has been shown to modulate SHH signalling, the regulatory factors involved in SUFU deubiquitination and their specific roles in MB pathogenesis remain largely undefined. Methods: Mass spectrometry and co‐immunoprecipitation were employed to identify the interaction between USP9X and SUFU. Clinical correlation analyses were conducted using MB tissue microarrays and publicly available datasets. Ubiquitination assays, functional cell‐based experiments, and orthotopic xenograft models were performed to evaluate the biological role of USP9X in SHH‐MB. Chaperone‐mediated autophagy (CMA) inhibitors were utilised to investigate their regulatory effects on USP9X expression and SHH‐MB progression. Results: Mass spectrometry identified the deubiquitinase ubiquitin‐specific protease 9X (USP9X) as a previously unrecognised SUFU‐binding partner. Notably, USP9X and SUFU exhibit a positive correlation in a MB tissue array, with both exhibiting low expression levels that are associated with adverse prognostic outcomes. Loss of USP9X in SHH‐MB enhances cell proliferation in vitro as well as orthotopic MB xenograft tumourgenicity in vivo. Mechanically, USP9X deubiquitinates and stabilises SUFU, thereby negatively regulating SHH signal transduction. Interestingly, SHH signalling promotes SUFU ubiquitination through CMA‐dependent degradation of USP9X protein levels, facilitating pathway activation. Combined inhibition of CMA and SHH pathway had a synergically therapeutic effect on SHH‐MB. Conclusions: These results establish CMA and USP9X as pivotal regulators of SHH medulloblastoma MB progression, emphasising their potential as novel therapeutic targets for medulloblastoma, and combinatorial inhibition of CMA and Smoothened (SMO) may provide a strategy to overcome intrinsic or acquired resistance to SMO monotherapy in SHH‐MB. Key points: USP9X suppresses SHH medulloblastoma progression by deubiquitinating SUFU. SHH promotes USP9X degradation through the CMA pathway. Combined inhibition of CMA and SHH pathway had a synergically therapeutic effect on SHH Medulloblastoma.
- Open Access
- 1 January 2026
- Published by Journal of Biomedical Research in Journal of Biomedical Research
- Vol. 40 (3) , 228-19
GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses
Medulloblastoma (MB) is the most common malignant tumor of the cerebellum in children. The SHH subgroup of MB (SHH-MB) is driven by aberrant activation of the Sonic Hedgehog (SHH) pathway; however, mutations in genes related to this pathway are relatively rare, posing challenges for therapeutic development. Glypican-6 (GPC6), a heparan sulfate proteoglycan, is highly expressed in SHH-MB. In this study, we demonstrate the synchronous expression of GPC6 with GLI1 in both the developing cerebellum and medulloblastoma. GPC6 promoted the cell proliferation, migration, and invasion in SHH-MB cell lines (DAOY and ONS-76). Consistently, GPC6 enhanced SHH pathway activity by upregulating GLI1 expression, supported ciliogenesis that is essential for signal transduction, and facilitated the secretion of SHH ligands via extracellular vesicles. These findings establish GPC6 as a critical regulator of SHH-MB progression and highlight its potential as a therapeutic target.
- 1 January 2026
- Published by Journal of Biomedical Research in Journal of Biomedical Research
- Vol. 40 (3) , 228-19
Open AccessGPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses
Medulloblastoma (MB) is the most common malignant tumor of the cerebellum in children. The SHH subgroup of MB (SHH-MB) is driven by aberrant activation of the Sonic Hedgehog (SHH) pathway; however, mutations in genes related to this pathway are relatively rare, posing challenges for therapeutic development. Glypican-6 (GPC6), a heparan sulfate proteoglycan, is highly expressed in SHH-MB. In this study, we demonstrate the synchronous expression of GPC6 with GLI1 in both the developing cerebellum and medulloblastoma. GPC6 promoted the cell proliferation, migration, and invasion in SHH-MB cell lines (DAOY and ONS-76). Consistently, GPC6 enhanced SHH pathway activity by upregulating GLI1 expression, supported ciliogenesis that is essential for signal transduction, and facilitated the secretion of SHH ligands via extracellular vesicles. These findings establish GPC6 as a critical regulator of SHH-MB progression and highlight its potential as a therapeutic target.
- Open Access
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Increasing Sufu gene dosage reveals its unorthodox role in promoting polydactyly and medulloblastoma tumorigenesis
Suppressor of fused (SUFU) is widely regarded as a key negative regulator of the sonic hedgehog (SHH) morphogenic pathway and a known tumor suppressor of medulloblastoma (MB). However, we report here that SUFU expression was markedly increased in 75% of specimens compiled in a tissue array comprising 49 unstratified MBs. The SUFU and GLI1 expression levels in this MB array showed strong positive correlation, which was also identified in a large public data set containing 736 MBs. We further report that increasing Sufu gene dosage in mice caused preaxial polydactyly, which was associated with the expansion of the Gli3 domain in the anterior limb bud and heightened Shh signaling responses during embryonic development. Increasing Sufu gene dosage also led to accelerated cerebellar development and, when combined with ablation of the Shh receptor encoded by Patched1 ( Ptch1 ), promoted MB tumorigenesis. These data reveal multifaceted roles of SUFU in promoting MB tumorigenesis by enhancing SHH signaling. This revelation clarifies potentially counterintuitive clinical observation of high SUFU expression in MBs and may pave way for novel strategies to reduce or reverse MB progression.
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Open AccessIncreasing Sufu gene dosage reveals its unorthodox role in promoting polydactyly and medulloblastoma tumorigenesis
Suppressor of fused (SUFU) is widely regarded as a key negative regulator of the sonic hedgehog (SHH) morphogenic pathway and a known tumor suppressor of medulloblastoma (MB). However, we report here that SUFU expression was markedly increased in 75% of specimens compiled in a tissue array comprising 49 unstratified MBs. The SUFU and GLI1 expression levels in this MB array showed strong positive correlation, which was also identified in a large public data set containing 736 MBs. We further report that increasing Sufu gene dosage in mice caused preaxial polydactyly, which was associated with the expansion of the Gli3 domain in the anterior limb bud and heightened Shh signaling responses during embryonic development. Increasing Sufu gene dosage also led to accelerated cerebellar development and, when combined with ablation of the Shh receptor encoded by Patched1 ( Ptch1 ), promoted MB tumorigenesis. These data reveal multifaceted roles of SUFU in promoting MB tumorigenesis by enhancing SHH signaling. This revelation clarifies potentially counterintuitive clinical observation of high SUFU expression in MBs and may pave way for novel strategies to reduce or reverse MB progression.
- 1 August 2023
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 101 (4) , 284-293
Hedgehog signal activates AMPK via Smoothened to promote autophagy and lipid degradation in hepatocytes
Studies in the past decade have shown that lipid droplets stored in liver cells under starvation are encapsulated by autophagosomes and fused to lysosomes via the endocytic system. Autophagy responds to a variety of environmental factors inside and outside the cell, so it has a complex signal regulation network. To this end, we first explored the role of Hedgehog (Hh) in autophagy and lipid metabolism. Treatment of normal mouse liver cells with SAG and GDC-0449 revealed elevated phosphorylation of AMP-activated protein kinase (AMPK) and increased lipidation of LC3. SAG, and GDC-0449 were agonist and antagonist of Smoothened (Smo) in canonical Hh pathway, respectively, but they played a consistent role in the regulation of autophagy in hepatocytes. Moreover, SAG and GDC-0449 did not affect the expression of glioma-associated oncogene (Gli1) and patched 1, suggesting the absence of canonical Hh signaling in hepatocytes. We further knocked down the Smo and found that the effects of SAG and GDC-0449 disappeared, indicating that the non-canonical Smo pathway was involved in the regulation of autophagy in hepatocytes. In addition, SAG and GDC-0449 promoted lipid degradation and inhibited lipid production signals. Knockdown of Smo slowed down the rate of lipid degradation rather than Sufu or Gli1, indicating that Hh signaling regulated the lipid metabolism via Smo. In summary, activates AMPK via Smo to promote autophagy and lipid degradation.
- 1 August 2023
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 101 (4) , 284-293
Hedgehog signal activates AMPK via Smoothened to promote autophagy and lipid degradation in hepatocytes
Studies in the past decade have shown that lipid droplets stored in liver cells under starvation are encapsulated by autophagosomes and fused to lysosomes via the endocytic system. Autophagy responds to a variety of environmental factors inside and outside the cell, so it has a complex signal regulation network. To this end, we first explored the role of Hedgehog (Hh) in autophagy and lipid metabolism. Treatment of normal mouse liver cells with SAG and GDC-0449 revealed elevated phosphorylation of AMP-activated protein kinase (AMPK) and increased lipidation of LC3. SAG, and GDC-0449 were agonist and antagonist of Smoothened (Smo) in canonical Hh pathway, respectively, but they played a consistent role in the regulation of autophagy in hepatocytes. Moreover, SAG and GDC-0449 did not affect the expression of glioma-associated oncogene (Gli1) and patched 1, suggesting the absence of canonical Hh signaling in hepatocytes. We further knocked down the Smo and found that the effects of SAG and GDC-0449 disappeared, indicating that the non-canonical Smo pathway was involved in the regulation of autophagy in hepatocytes. In addition, SAG and GDC-0449 promoted lipid degradation and inhibited lipid production signals. Knockdown of Smo slowed down the rate of lipid degradation rather than Sufu or Gli1, indicating that Hh signaling regulated the lipid metabolism via Smo. In summary, activates AMPK via Smo to promote autophagy and lipid degradation.
- Open Access
HIB/SPOP inhibits Ci/Gli-mediated tumorigenesis by modulating the RNA Polymerase II components stabilities
- Open Access
- 10 March 2023
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 25 (3) , 233-243
Anemarrhenasaponin I suppresses ovarian cancer progression via inhibition of SHH signaling pathway
Objectives: The Sonic hedgehog (SHH) signaling is essential in animal development and tissue homeostasis. Aberrant activation of SHH pathway has been implicated in tumorigenesis and progression of several cancers, including ovarian cancer. Therefore, targeting SHH pathway may pave the way for successful ovarian cancer treatment. Methods: To identify the potential SHH inhibitors from traditional Chinese medicines, we herein employed two in vitro cell models. In addition, western blotting and quantitative real-time PCR were performed to evaluate the inhibitory activity of Anemarrhenasaponin I (An-I) on SHH signaling in ovarian cancer cells. Cell proliferation assay and transwell assay were used to assess the effect of An-I on tumorigenicity. We also applied RNA-seq to examine the potential mechanism of An-I against ovarian cancer. Results: Drug screening results showed that An-I drastically inhibited SHH signaling. More importantly, An-I effectively suppressed ovarian cancer cell proliferation and aggressiveness. RNA-seq-based transcriptome data showed that An-I affected ovarian cancer cells by suppressing SHH-WNT-Matrix metalloproteinases (MMPs) pathway. Conclusions: An-I suppressed ovarian cancer progression by inhibiting SHH-WNT-MMP signaling transduction, providing a new treatment strategy for ovarian cancer.
- 10 March 2023
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 25 (3) , 233-243
Open AccessAnemarrhenasaponin I suppresses ovarian cancer progression via inhibition of SHH signaling pathway
Objectives: The Sonic hedgehog (SHH) signaling is essential in animal development and tissue homeostasis. Aberrant activation of SHH pathway has been implicated in tumorigenesis and progression of several cancers, including ovarian cancer. Therefore, targeting SHH pathway may pave the way for successful ovarian cancer treatment. Methods: To identify the potential SHH inhibitors from traditional Chinese medicines, we herein employed two in vitro cell models. In addition, western blotting and quantitative real-time PCR were performed to evaluate the inhibitory activity of Anemarrhenasaponin I (An-I) on SHH signaling in ovarian cancer cells. Cell proliferation assay and transwell assay were used to assess the effect of An-I on tumorigenicity. We also applied RNA-seq to examine the potential mechanism of An-I against ovarian cancer. Results: Drug screening results showed that An-I drastically inhibited SHH signaling. More importantly, An-I effectively suppressed ovarian cancer cell proliferation and aggressiveness. RNA-seq-based transcriptome data showed that An-I affected ovarian cancer cells by suppressing SHH-WNT-Matrix metalloproteinases (MMPs) pathway. Conclusions: An-I suppressed ovarian cancer progression by inhibiting SHH-WNT-MMP signaling transduction, providing a new treatment strategy for ovarian cancer.
- Open Access
- 22 January 2023
- Published by Springer Nature in Cell & Bioscience
- Vol. 13 (1) , 1-17
AMPK attenuates SHH subgroup medulloblastoma growth and metastasis by inhibiting NF-κB activation
Background: Medulloblastoma (MB) is one of the most common malignant pediatric brain tumors. Metastasis and relapse are the leading causes of death in MB patients. The initiation of the SHH subgroup of MB (SHH-MB) is due to the aberrant activation of Sonic Hedgehog (Shh) signaling. However, the mechanisms for its metastasis are still unknown. Results: AMP-dependent protein kinase (AMPK) restrains the activation of Shh signaling pathway, thereby impeding the proliferation of SHH-MB cells. More importantly, AMPK also hinders the growth and metastasis of SHH-MB cells by regulating NF-κB signaling pathway. Furthermore, Vismodegib and TPCA-1, which block the Shh and NF-κB pathways, respectively, synergistically restrained the growth, migration, and invasion of SHH-MB cells. Conclusions: This work demonstrates that AMPK functions through two signaling pathways, SHH-GLI1 and NF-κB. AMPK-NF-κB axis is a potential target for molecular therapy of SHH-MB, and the combinational blockade of NF-κB and Shh pathways confers synergy for SHH-MB therapy.
- 22 January 2023
- Published by Springer Nature in Cell & Bioscience
- Vol. 13 (1) , 1-17
Open AccessAMPK attenuates SHH subgroup medulloblastoma growth and metastasis by inhibiting NF-κB activation
Background: Medulloblastoma (MB) is one of the most common malignant pediatric brain tumors. Metastasis and relapse are the leading causes of death in MB patients. The initiation of the SHH subgroup of MB (SHH-MB) is due to the aberrant activation of Sonic Hedgehog (Shh) signaling. However, the mechanisms for its metastasis are still unknown. Results: AMP-dependent protein kinase (AMPK) restrains the activation of Shh signaling pathway, thereby impeding the proliferation of SHH-MB cells. More importantly, AMPK also hinders the growth and metastasis of SHH-MB cells by regulating NF-κB signaling pathway. Furthermore, Vismodegib and TPCA-1, which block the Shh and NF-κB pathways, respectively, synergistically restrained the growth, migration, and invasion of SHH-MB cells. Conclusions: This work demonstrates that AMPK functions through two signaling pathways, SHH-GLI1 and NF-κB. AMPK-NF-κB axis is a potential target for molecular therapy of SHH-MB, and the combinational blockade of NF-κB and Shh pathways confers synergy for SHH-MB therapy.
- Open Access
- 9 July 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 691317
The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer
Breast cancer is one of the most common malignant tumors in women worldwide. Circular RNA (circRNA) is a class of structurally stable non-coding RNA with a covalently closed circular structure. In recent years, with the development of high-throughput RNA sequencing, many circRNAs have been discovered and have proven to be clinically significant in the development and progression of breast cancer. Importantly, several regulators of circRNA biogenesis have been discovered. Here, we systematically summarize recent progress regarding the network of regulation governing the biogenesis, degradation, and distribution of circRNAs, and we comprehensively analyze the functions, mechanisms, and clinical significance of circRNA in breast cancer.
- 9 July 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 691317
Open AccessThe Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer
Breast cancer is one of the most common malignant tumors in women worldwide. Circular RNA (circRNA) is a class of structurally stable non-coding RNA with a covalently closed circular structure. In recent years, with the development of high-throughput RNA sequencing, many circRNAs have been discovered and have proven to be clinically significant in the development and progression of breast cancer. Importantly, several regulators of circRNA biogenesis have been discovered. Here, we systematically summarize recent progress regarding the network of regulation governing the biogenesis, degradation, and distribution of circRNAs, and we comprehensively analyze the functions, mechanisms, and clinical significance of circRNA in breast cancer.
- Open Access
- 21 May 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-15
SPOP–PTEN–SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway
Although E3 ligase Speckle type BTB/POZ protein (SPOP) promotes tumorigenesis by acting as a key regulatory hub in clear cell renal cell carcinoma (ccRCC), the detailed molecular mechanism remains unclear. Here, we demonstrate that a well-known tumor suppressor, Suppressor of Fused (SUFU), is downregulated by SPOP. Interestingly, this downregulation depends on cullin-3(Cul3)-SPOP E3 ligase, but SUFU is not a direct substrate of SPOP. Phosphatase and tensin homolog (PTEN), a ubiquitinated substrate of SPOP, is involved in SPOP-mediated SUFU reduction. Importantly, inhibition of SUFU leads to elevated SHH and WNT signaling, consequently rescuing the reduced proliferation, migration, and invasion abilities of ccRCC cells caused by SPOP-knockdown. Moreover, combinatorial treatment with SHH and WNT inhibitors shows more effective for suppressing ccRCC cell proliferation and aggressiveness. These findings demonstrate that a novel SPOP–PTEN–SUFU axis promotes ccRCC carcinogenesis by activating SHH and WNT pathway, providing a new treatment strategy for ccRCC.
- 21 May 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-15
Open AccessSPOP–PTEN–SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway
Although E3 ligase Speckle type BTB/POZ protein (SPOP) promotes tumorigenesis by acting as a key regulatory hub in clear cell renal cell carcinoma (ccRCC), the detailed molecular mechanism remains unclear. Here, we demonstrate that a well-known tumor suppressor, Suppressor of Fused (SUFU), is downregulated by SPOP. Interestingly, this downregulation depends on cullin-3(Cul3)-SPOP E3 ligase, but SUFU is not a direct substrate of SPOP. Phosphatase and tensin homolog (PTEN), a ubiquitinated substrate of SPOP, is involved in SPOP-mediated SUFU reduction. Importantly, inhibition of SUFU leads to elevated SHH and WNT signaling, consequently rescuing the reduced proliferation, migration, and invasion abilities of ccRCC cells caused by SPOP-knockdown. Moreover, combinatorial treatment with SHH and WNT inhibitors shows more effective for suppressing ccRCC cell proliferation and aggressiveness. These findings demonstrate that a novel SPOP–PTEN–SUFU axis promotes ccRCC carcinogenesis by activating SHH and WNT pathway, providing a new treatment strategy for ccRCC.
- Open Access
- 2 March 2021
- Published by Springer Nature in Cell & Bioscience
- Vol. 11 (1) , 1-15
Deletion at an 1q24 locus reveals a critical role of long noncoding RNA DNM3OS in skeletal development
Background: Skeletal development and maintenance are complex processes known to be coordinated by multiple genetic and epigenetic signaling pathways. However, the role of long non-coding RNAs (lncRNAs), a class of crucial epigenetic regulatory molecules, has been under explored in skeletal biology. Results: Here we report a young patient with short stature, hypothalamic dysfunction and mild macrocephaly, who carries a maternally inherited 690 kb deletion at Chr.1q24.2 encompassing a noncoding RNA gene, DNM3OS, embedded on the opposite strand in an intron of the DYNAMIN 3 (DNM3) gene. We show that lncRNA DNM3OS sustains the proliferation of chondrocytes independent of two co-cistronic microRNAs miR-199a and miR-214. We further show that nerve growth factor (NGF), a known factor of chondrocyte growth, is a key target of DNM3OS-mediated control of chondrocyte proliferation. Conclusions: This work demonstrates that DNM3OS is essential for preventing premature differentiation of chondrocytes required for bone growth through endochondral ossification.
- 2 March 2021
- Published by Springer Nature in Cell & Bioscience
- Vol. 11 (1) , 1-15
Open AccessDeletion at an 1q24 locus reveals a critical role of long noncoding RNA DNM3OS in skeletal development
Background: Skeletal development and maintenance are complex processes known to be coordinated by multiple genetic and epigenetic signaling pathways. However, the role of long non-coding RNAs (lncRNAs), a class of crucial epigenetic regulatory molecules, has been under explored in skeletal biology. Results: Here we report a young patient with short stature, hypothalamic dysfunction and mild macrocephaly, who carries a maternally inherited 690 kb deletion at Chr.1q24.2 encompassing a noncoding RNA gene, DNM3OS, embedded on the opposite strand in an intron of the DYNAMIN 3 (DNM3) gene. We show that lncRNA DNM3OS sustains the proliferation of chondrocytes independent of two co-cistronic microRNAs miR-199a and miR-214. We further show that nerve growth factor (NGF), a known factor of chondrocyte growth, is a key target of DNM3OS-mediated control of chondrocyte proliferation. Conclusions: This work demonstrates that DNM3OS is essential for preventing premature differentiation of chondrocytes required for bone growth through endochondral ossification.